About the CardioGuide Implant System
The CardioGuide Implant System is designed to analyze fluoroscopy images and create 3-D imaging of the heart for transvenous left-ventricular lead implants. The components currently offered in the system include:
-- CardioGuide software and work station, which includes a dedicated computer and monitor that are used to calculate anatomical measurements and provide lead navigation support.-- Physician monitor, which displays the implant system inside the procedure room or cath lab.-- Tablet computer, which includes a touch screen and stylus and is used as a tableside console in the procedure room.-- Markers that are placed on the patient's chest to automatically calibrate the system.
In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers worldwide.
About Medtronic of Canada Ltd.
Medtronic of Canada Ltd. is a trusted Canadian leader delivering innovative health system solutions and advanced medical technologies to alleviate pain, restore health, and extend life in the areas of cardiovascular medicine, diabetes, spinal and neurosurgery, and ear, nose, throat surgery. Medtronic is proud to employ more than 700 Canadians. Headquartered in Brampton, Ontario, Medtronic has regional offices in Vancouver and Montreal, including a manufacturing facility, Medtronic CryoCath, located in Pointe-Claire, Quebec. www.medtronic.ca
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.
About Paieon Inc.
Paieon is a medical imaging company pioneering in the field of real-time imaging for cardiac navigation. Paieon's mission is to develop progressive cardiac navigation imaging solutions that bridge between the imaging world and implantable devices, adding its valuable decision tools to support physicians and their patients throughout interventional cardiac procedures.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
(1) Abraham WT, Fisher WG, Smith AL, et al. Cardiac Resynchronization in Chronic Heart Failure. N Engl J Med. 2002 Jun 13;346(24):1845-53.
(2) Saba S, Marek J, Schwartzmann D, et al. Echocardiography-Guided Left Ventricular Lead Placement for Cardiac Resynchronization Terhapy: Results of the Speckle Tracking Assisted Resynchronization Therapy for Electrode Region (STARTER) Trial. Circulation Heart Failure, online, 2013.
(3) Khan FZ, Virdee MS, Palmer CR, et al. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. JACC. April 24, 2012;59(17):1509-18.
(4) Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2012;126:1784-1800.
(5) Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. April 14, 2005;352(15):1539-1549.
(6) Medtronic internal research. (Cardiac Navigation System Value Proposition and Pricing, December 2011).
Medtronic of Canada Ltd.
Medtronic of Canada Ltd.